11/5/2026

speaker
Maria
Conference Operator

Greetings and welcome to the Colletium Pharmaceutical Third Quarter 2026 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during this conference call, please press star zero on your telephone keypad. Please note that this conference call is being recorded. I will now turn the call over to Ian Karp, Head of Investor Relations. Thank you. You may begin.

speaker
Ian Karp
Head of Investor Relations

Great. Thanks, Maria. And welcome to Collegium Pharmaceutical's third quarter 2026 earnings conference call. I'm joined today by Vikram Karnani, our president and chief executive officer, and Colleen Tupper, our chief financial officer. Before we begin today's call, we want to remind participants that none of the information presented today is intended to be promotional and that any forward-looking statements made today are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. We are cautioned that such forward-looking statements involve risks and uncertainties as detailed in the company's periodic reports filed with the Securities and Exchange Commission. Our future results may differ materially from our current expectations discussed today. Our earnings press release and this call will include discussion of certain non-GAAP information. You can find our earnings press release, including relevant non-GAAP reconciliations, on our corporate website. And with that, I'll now turn the call over to our President and CEO, Vikram Karnani.

speaker
Vikram Karnani
President and Chief Executive Officer

Thank you, Ian. Good morning, everyone, and thank you for joining our third quarter 2026 earnings call. Collegium is a dynamic commercial stage biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions. Our success is built upon our proven ability to acquire, integrate, and grow differentiated medicines while creating long-term shareholder value. This strategy has established a portfolio of six differentiated medicines Reflecting the significant evolution our company has undertaken over the past several years, ADHD has become our lead growth driver, accounting for more than 36% of total revenue, up from just 19% last year. With Jornet PM and Astaris, we have two complementary medicines supported by an expanding commercial platform to drive future growth. Meanwhile, Our pain portfolio continues to generate robust cash flows providing the financial flexibility to invest in our ADHD portfolio and further diversify our business. The team at Collegium remains focused, invigorated, and committed to making a meaningful difference in the lives of patients and creating long-term value for our shareholders. We delivered record quarterly net revenue of $216.3 million, up 3% year-over-year, driven by growth in ADHD during the important back-to-school season. Key achievements this quarter included Dornapium prescriptions grew by 16%, generating a record $51.9 million in net revenue, up 24% year-over-year. Jordan APM prescribers also reached another all-time high with nearly 33,000 healthcare providers writing Jordan APM prescriptions in the quarter, up 19% over Q3 of last year. Our investments in Jordan APM are translating into broader prescriber adoption and continued prescription growth. ASTAR has generated 26.5 million in net revenue during its first full quarter under our ownership. Prescriptions grew nearly 2% year-over-year following a decline in 2025. This is an early indication of the opportunity to grow Astaris through our expanded ADHD commercial platform. Our pain portfolio generated 138 million in revenue during the quarter, continuing to make a meaningful contribution to our business. Performance was in line with our expectations and consistent with our 2026 full-year financial guidance. Turning now to other recent corporate updates. We are continuously seeking ways to support the ADHD patient community, and in October, which was ADHD Awareness Month, we announced two new initiatives. First, we launched Start Talking ADHD, our online resource hub offering practical guides to people living with ADHD and their caregivers. And next, we established a new multi-year partnership with Boston Legacy FC, Boston's professional women's soccer club, focused on promoting inclusion and accessibility through youth coach training and annual sports for all summit and sensory inclusion programs designed to support neurodivergent children and their families, including those living with ADHD. We also further advanced our capital allocation strategy by returning capital to shareholders through a $50 million accelerated share repurchase program announced in the third quarter. We expect to complete the full repurchase amount before the end of the year and have $100 million remaining on our share repurchase program that was authorized by our board last July. As we look toward the end of 2026 and move into next year, we remain focused on three key strategic priorities. Growing our ADHD business, maximizing the value of our pain portfolio, and strategically deploying capital to create long-term shareholder value. Our ADHD portfolio performed particularly well in the third quarter, further supported by our promotional activities, expanded sales force, and the back-to-school season. The momentum across our ADHD business has enabled us to reaffirm our full-year 2026 guidance, which includes $190 to $200 million in journey PM revenues, a 31% increase year-over-year at the midpoint, and $65 to $75 million in partial-year ASTARIS revenues. In pain, our focus is on maximizing portfolio value and cash generation. That cash flow supports investment in ADHD and provides flexibility to pursue business development, repay debt, and return capital to shareholders. Turning to our leadership position in ADHD, we now have a unified commercial organization focused on accelerating growth and maximizing operational leverage. And at the foundation of this franchise are Joan APM and Astaris, Two differentiated and complementary medicines that serve different patient types, allowing us to address the unmet needs of a wide range of patients. Both medicines can last all day and offer a smooth offset, helping to avoid a treatment crash, which can be seen with other ADHD medicines. The main differences between Jornet and Astaris are in the timing of their symptom control. Jornet PM is the first and only stimulant dosed at night. delivering symptom control without delay upon awakening. Jordan APM is often preferred by the patient whose symptoms are particularly challenging first thing in the morning and who needs their all-day symptom control to start immediately upon awakening. ASTARIS is the first and only ADHD stimulant treatment with both fast and long-acting medicines in one capsule, delivering rapid, all-day symptom control. ASTARIS is often preferred by the patient who has more variability in their daily schedule, and needs the flexibility of rapid onset symptom control and efficacy to last later into the evening. In fact, driven by our targeted investments and enhanced commercial efforts, HCP perceptions of Jordan APM are increasingly positive. Based on market research completed earlier this year, HCPs had a high favorability rating and ranked Jordan APM as the number one branded ADHD medicine in terms of product differentiation. with a score significantly higher than all other medicines in the same category. The same market research conducted prior to Collegium's acquisition of Astaris also yielded important insights into Astaris' market opportunity. Namely, it was viewed as meaningfully differentiated in the ADHD treatment landscape and more than half of physicians surveyed indicated an intent to increase prescribing in the future. We believe there is a significant opportunity to increase HCP perception of Astaris in the months and quarters ahead by utilizing our enhanced ADHD commercial platform. And encouragingly, Collegium ranked number one in reputation among pharmaceutical companies specializing in ADHD. Combined, Jordan APM and Astaris now command approximately 55% share of the total branded long-acting methylphenidate market. With the majority of the long-acting methylphenidate market comprised of generics, we believe there remains a significant opportunity to capture additional share, particularly among patients who are dissatisfied with their current generic treatment. This quarter, Jonay PM remained the fastest-growing stimulant for the treatment of ADHD and demonstrated strong performance across a number of key metrics. Prescriptions grew 16% year-over-year. Prescribers hit an all-time high with nearly 33,000 healthcare providers writing Jornapium prescriptions, up 19% year-over-year. Jornapium's share in the branded long-acting methylphenidate market also hit an all-time high at approximately 30%, up 6.5 percentage points year-over-year. We also saw solid growth across both the pediatric and adult segments. In the pediatric and adolescent segment, which represents about 80% of our business, total prescriptions grew 13% year over year. Growth was even stronger in the adult segment, representing about 20% of our overall prescriptions, which grew 27% year over year. New to brand prescriptions provided another measure of potentially accelerating demand, capturing patients who were new to Journée or have not received a prescription in the prior 12 months. In September, the first full month of the back-to-school season, new-to-brand prescriptions grew 22% year-over-year, and that momentum has accelerated in October. Bolstered by the back-to-school season, Jordan APM delivered particularly strong performance this quarter, and our priority is to sustain prescription growth throughout the remainder of the year. This was also our first full quarter promoting Astaris, and we are just beginning to see the benefits of having two differentiated and complementary ADHD medicines in our portfolio. In addition, prior to our acquisition of Astaris, commercial investment in the product was limited and at times inconsistent. This likely contributed to Astaris total prescriptions declining by nearly 2% in 2025. Despite these declining volumes, Market research suggested that Astaris was the second most differentiated stimulant brand following Journey PM. With its strong brand fundamentals, coupled with our commercial expertise and track record of growing acquired products, we believe that we can maximize Astaris' growth potential in the years ahead. And we have already started to see early signs of success, with prescriptions up nearly 2% year over year in the third quarter, following an annual prescription decline in 2025. Importantly, Astartes has IP protection through 2037, extending the lifecycle of our commercial portfolio and giving us additional time to maximize the reach and full value of Astartes. Following the close of the Astartes acquisition in May, we were able to rapidly and seamlessly integrate Astartes into our commercial infrastructure. We have made targeted investments, expanding our ADHD commercial team and marketing capabilities. We grew our ADHD sales force to about 190 reps, up from 180 prior to the acquisition, and our target HCPs to about 27,000, up from 21,000 pre-expansion in 25. We also recently expanded our medical affairs team to better support both products from a clinical standpoint. All of our sales representatives were fully trained and selling both products to their targeted HCPs in July ahead of the back-to-school season to maximize impact. We are now deploying our target HCP, patient, and caregiver marketing efforts for both Journey PM and ASTARS. Early initiatives include focused AI-targeted digital marketing campaigns, peer-to-peer programming, and increasingly shifting investment towards awareness-driving brand campaigns built on each product's clinical strengths. Turning to our responsible pain management business. This portfolio comprised of the BUCA, XTAMSA, and NISINTA continues to provide a solid foundation for Collegium that, through its strong cash generation, provides financial flexibility to invest in the growth of our ADHD business, execute disciplined business development opportunities, and return capital to shareholders. Delbuca delivered solid performance again this quarter, with revenues of $57.7 million, broadly flat year-over-year and sequentially. Extension revenue declined year-over-year, reflecting continued peer pressure across the branded long-acting opioid market that accelerated at the start of this year. Prescription levels, however, increased slightly in each sequential quarter of 2026, including approximately 3% growth in Q3 compared to Q2. Looking ahead, we expect similar prescription levels for the remainder of 2026 and are encouraged that a large payer representing about 15 Stamsa into an exclusive formulary position on January 1, 2027. This inter-franchise revenue also declined year over year, driven largely by generic competition. But encouragingly, prescription volumes for our branded products have remained relatively consistent over the past three to four months, and pricing for the authorized generics was stable between Q2 and Q3. Our sales expectations for the remainder of the year are appropriately reflected in our full-year revenue guidance. In summary, while we are seeing some expected pressure on our legacy paying business this year, particularly to Nusenta, we continue to expect this business to remain a durable contributor to revenue, earnings, and cash flow in the years ahead. I will now hand the call over to Colleen to discuss our financial highlights before I return with some concluding remarks.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API

Investor presentation